Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | LDHB | P07195 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483368 | 0.78 | LDHA (0.38) | LDHALDHBPIM1PIM3PIM2 | |
| SCHEMBL14237447 | 0.75 | PIM2 (0.44) | PIM1PIM3PIM2PIK3CD | |
| SCHEMBL3825299 | 0.75 | PIM2 (0.44) | PIM1PIM3PIM2PIK3CD | |
| SCHEMBL2211261 | 0.74 | LDHA (0.46) | LDHALDHBPIM1PIM3PIM2 | |
| SCHEMBL376384 | 0.72 | HCRTR2 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL3826467 | 0.72 | PIM1 (0.41) | PIM1PIM3PIM2PIK3CD | |
| SCHEMBL18035799 | 0.71 | GSK3A (0.45) | PIK3CD | |
| SCHEMBL18035801 | 0.71 | GSK3A (0.45) | PIK3CD | |
| SCHEMBL482351 | 0.71 | IRAK1 (0.53) | — | |
| SCHEMBL17075714 | 0.71 | IRAK1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3053923-B1 | TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS | KOREA RES INST CHEMICAL TECH (KR) | 2018-04-11 | — | — | EP | disclosed |
| EP-3053923-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2016-08-10 | — | — | EP | disclosed |
| US-9403831-B2 | Triazolopyrazine derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-08-02 | — | — | US | disclosed |
| US-20150259350-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | HANDOK INC. (KR) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259350-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | MET, RET, BRAF | LDHA 4779/4885LDHB 4772/4885PIM1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.